source
- Rapport Therapeutics reports Phase 2 success for RAP-219 in bipolar mania trialRapport Therapeutics announced that its lead candidate RAP-219 met the primary endpoint in a Phase 2 study of adults with acute bipolar mania. The double-blind trial enrolled 253 patients and meas…
- Alnylam shares tumble to $250 after cutting full-year revenue guidance for its TTR franchiseAlnylam Pharmaceuticals saw its share price slide to about $250 after the company lowered its full-year revenue outlook for its transthyretin (TTR) franchise. The guidance cut, announced in July, f…